Análisis de minimización de costos de brolucizumab para la DMAEh en Colombia / Cost minimization analysis of brolucizumab for wAMD in Colombia
Rev. Soc. Colomb. Oftalmol
;
56(1): 6-15, 2023. ilus (graf)
Article
in Spanish
| LILACS, COLNAL
| ID: biblio-1444856
RESUMEN
Introducción:
La degeneración macular asociada a la edad húmeda (DMAEh) tiene un impacto negativo en la calidad de vida. Brolucizumab es una alternativa efectiva y segura.Objetivo:
Evaluar la diferencia en costos anuales de tratamiento entre brolucizumab 6 mg (esquema 6 LP â q12/q8), ranibizumab 0.5 mg (esquema Treat and Extend [TREX]) y aflibercept 2 mg (esquema TREX) para pacientes con DMAEh en Colombia. Materiales ymétodos:
Se realizó un análisis de minimización de costos con un horizonte temporal de cinco años y una tasa de descuento del 5%. Se consideraron costos médicos directos mediante fuentes locales. Se realizó un análisis de sensibilidad univariante.Resultados:
El uso de brolucizumab implica un ahorro anual del 7.63% vs. aflibercept y del 12.8% vs. ranibizumab. Estos resultados fueron consistentes con los análisis de sensibilidad.Conclusiones:
En un horizonte temporal de cinco años, brolucizumab es una tecnología costo-ahorradora para el tratamiento de la DMAEh en Colombia.ABSTRACT
Background:
Wet age-related macular degeneration (wAMD) has a negative impact on quality of life. Brolucizumab is an effective and safe alternative.Objective:
To assess the difference in annual treatment costs between brolucizumab 6 mg (6 LP â q12/q8 schedule), ranibizumab 0.5 mg (Treat and Extend [TREX schedule]), and aflibercept 2 mg (TREX schedule), for patients with AMD in Colombia. Materials andmethods:
A cost minimization analysis was performed with a time horizon of five years and a discount rate of 5%. Direct medical costs were considered through local sources. A univariate sensitivity analysis was performed.Results:
The use of brolucizumab implies an annual saving of 7.63% vs. aflibercept and 12.8% vs. ranibizumab. These results were consistent with the sensitivity analyses.Conclusions:
In a time horizon of 5 years, brolucizumab is a cost-saving technology for the treatment of AMD in ColombiaSubject(s)
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Wet Macular Degeneration
Type of study:
Health economic evaluation
Limits:
Female
/
Humans
Country/Region as subject:
South America
/
Colombia
Language:
Spanish
Journal:
Rev. Soc. Colomb. Oftalmol
Journal subject:
Ophthalmology
Year:
2023
Type:
Article
Affiliation country:
Colombia
Institution/Affiliation country:
Pontificia Universidad Javeriana/CO
Similar
MEDLINE
...
LILACS
LIS